Max Piffoux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Max Piffoux has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Benoit You
Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Hospices Civils of Lyon, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921, Oullins, France; GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire), France; GINEGEPS (GINEco Group on Early Phase Studies), France; Hospices Civils de Lyon, Lyon, France
18 shared publications - Julien Péron
Université Claude Bernard Lyon 1, F-69003 Lyon, France
18 shared publications - Audrey Gelot
Plateforme de Recherche clinique de l’Institut de Cancérologie des Hospices Civils de Lyon, Hospices Civils de Lyon, Lyon, France. 5
17 shared publications - Christophe Sajous
Department of Oncology, Hospices Civils de Lyon, Lyon, France
17 shared publications - David Dayde
Plateforme de recherche clinique de l‘Institut de Cancérologie des Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon , Pierre-Bénite 69495
17 shared publications - Gaelle Lescuyer
Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Hospices Civils of Lyon, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921, Oullins, France; Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France
17 shared publications
Latest Publications
- 24 August 2026
- Published by Elsevier in Molecular Therapy
- Vol. 34 (9) , 5042-5044
Hepatocyte-like cell transplantation for urea cycle disorders: Toward a functional detoxifying bioimplant
- 24 August 2026
- Published by Elsevier in Molecular Therapy
- Vol. 34 (9) , 5042-5044
Hepatocyte-like cell transplantation for urea cycle disorders: Toward a functional detoxifying bioimplant
- Top Cited PapersOpen Access
- 6 May 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (1) , 236-244
Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment
Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales. Only scarce and partial monoclonal antibody life cycle assessments (LCAs) are reported. We estimate the cradle‐to‐pharmacy gate carbon footprint of monoclonal antibodies from the pharmacopeia on the market ( n = 103) using the full life cycle inventory of the medicines, encompassing antibody production, packaging production, transport, medicine manufacturing, and associated corporate emissions using a hybrid LCA/environmentally extended input–output model. Monoclonal antibody‐based drugs have an important carbon footprint with a mean of 169.7 kgCO 2 e/vial or prefilled syringe (95% CI 10.1–621.1) and 371.4 kgCO 2 e/month (95% CI 23.1–1,479.5) vs. 14.1 kgCO 2 e/month (95% CI 0.33–36.2) for an oral treatment. A large fraction of emissions is emerging from corporate emissions. The 95% CI surrounding these estimations is about ±35%. Among subparts, antibody production emissions largely vary from 7.1 to 20,206 kgCO 2 e/g of antibody (mean 472 kgCO 2 e/g, 95% CI 8.2–2,529), depending on the production scale. As an illustration, the carbon footprint of second‐line treatment options in rheumatoid arthritis ranges from 286 to 2,047 kgCO 2 e/year. In cancer immunotherapy, alternative weight‐adjusted dosing strategies lead to a 10–20% mitigation in greenhouse gas emissions, while “low‐dose” strategies may mitigate emissions by 2‐ to 10‐fold. Antibody‐based drugs have a significant carbon footprint, although highly variable. This database allows for a better understanding of the carbon footprint associated with these drugs, in order to better eco‐design care pathways.
- 6 May 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (1) , 236-244
Top Cited PapersOpen AccessCarbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment
Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales. Only scarce and partial monoclonal antibody life cycle assessments (LCAs) are reported. We estimate the cradle‐to‐pharmacy gate carbon footprint of monoclonal antibodies from the pharmacopeia on the market ( n = 103) using the full life cycle inventory of the medicines, encompassing antibody production, packaging production, transport, medicine manufacturing, and associated corporate emissions using a hybrid LCA/environmentally extended input–output model. Monoclonal antibody‐based drugs have an important carbon footprint with a mean of 169.7 kgCO 2 e/vial or prefilled syringe (95% CI 10.1–621.1) and 371.4 kgCO 2 e/month (95% CI 23.1–1,479.5) vs. 14.1 kgCO 2 e/month (95% CI 0.33–36.2) for an oral treatment. A large fraction of emissions is emerging from corporate emissions. The 95% CI surrounding these estimations is about ±35%. Among subparts, antibody production emissions largely vary from 7.1 to 20,206 kgCO 2 e/g of antibody (mean 472 kgCO 2 e/g, 95% CI 8.2–2,529), depending on the production scale. As an illustration, the carbon footprint of second‐line treatment options in rheumatoid arthritis ranges from 286 to 2,047 kgCO 2 e/year. In cancer immunotherapy, alternative weight‐adjusted dosing strategies lead to a 10–20% mitigation in greenhouse gas emissions, while “low‐dose” strategies may mitigate emissions by 2‐ to 10‐fold. Antibody‐based drugs have a significant carbon footprint, although highly variable. This database allows for a better understanding of the carbon footprint associated with these drugs, in order to better eco‐design care pathways.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Physical and interdisciplinary approaches of the extracellular vesicle field : new tools and techniques toward clinical translation in regenerative medicine and drug delivery
Approches interdisciplinaires du domaine des vésicules extracellulaires : nouvelles méthodes et outils pour le transfert en clinique en médecine régénérative et délivrance de médicaments: Les vésicules extracellulaires sont des nano-vésicules (100nm) comprenant les exosomes, microvesicules et corps apoptotiques, sécrétées par toutes les cellules de l’organisme. Elles ont des rôles physiologiques et physiopathologiques dans l’hémostase, l’inflammation, la transmission d’information et de molécules biologiques, les métastases, ou la régénération tissulaire. Par exemple, des vésicules issues de cellules souches mésenchymateuses ont le même effet que leur cellule mère dans la régénération du myocarde infarci, mais ont beaucoup d’avantages par rapport à ces dernières : possibilité de les conserver au congélateur, peu immunogènes, ne provoquant pas d’embolies, pas de risque de différentiation anarchique, etc. Toutefois, l’utilisation en clinique de ces vésicules reste difficile pour des raisons pratiques : très faible production par les cellules, difficulté à les caractériser, méthodes de chargement avec des agents thérapeutique peu reproductible, méthodes d’imagerie ou de d’ingénierie peu efficientes, etc. Nous avons développé des méthodes pour répondre à ces défis, croisant la biologie, la pharmacie et la physique, et avons pu découvrir que certaines de ces techniques pouvaient être utilisées dans d’autres domaines et pour d’autres indications. En pratique, pour répondre au problème de la caractérisation des vésicules, nous avons proposé une nouvelle méthode d’imagerie utilisant le microscope électronique en cellule liquide « in situ » pour observer des vésicules dans leur milieu liquide en temps réel, et peut être utilisé pour observer d’autres matériaux et phénomènes comme les liposomes ou des processus biologiques. Nous avons proposé une nouvelle méthode de chargement des vésicules avec des molécules thérapeutiques en les fusionnant avec des liposomes, permettant la délivrance d’agents de chimiothérapie plus efficacement que des liposomes. La méthode de production des vésicules à grand rendement a nécessité 3 d’itérations successives, toutes basées sur le même concept de vésiculation induite par une contrainte mécanique, et a abouti à une méthode efficace, scalable, et conformes aux standards de production pharmaceutique. La protéomique de ces vésicules montre des expressions de protéines plus proche d’un sous type de vésicule issues de la membrane plasmique appelées microvésicules. Les vésicules issues de cette méthode ont été testées in vitro avec succès, induisent un phénotype régénératif dans des modèles cicatrisation de fistule cutanéo-digestives et des modèles murins d’insuffisance cardiaque chronique. D’autres études sur les vésicules produites par cette méthode sont en cours sur la régénération osseuse, articulaire et cérébrale, ou la délivrance de médicaments et sur l’inhibition du phénomène métastatique en cancérologie. Nous commençons aujourd’hui à défricher le transfert de ces vésicules en clinique par le biais de productions en conditions pharmaceutiques dites et de la mise en place d’une start-up.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Physical and interdisciplinary approaches of the extracellular vesicle field : new tools and techniques toward clinical translation in regenerative medicine and drug delivery
Approches interdisciplinaires du domaine des vésicules extracellulaires : nouvelles méthodes et outils pour le transfert en clinique en médecine régénérative et délivrance de médicaments: Les vésicules extracellulaires sont des nano-vésicules (100nm) comprenant les exosomes, microvesicules et corps apoptotiques, sécrétées par toutes les cellules de l’organisme. Elles ont des rôles physiologiques et physiopathologiques dans l’hémostase, l’inflammation, la transmission d’information et de molécules biologiques, les métastases, ou la régénération tissulaire. Par exemple, des vésicules issues de cellules souches mésenchymateuses ont le même effet que leur cellule mère dans la régénération du myocarde infarci, mais ont beaucoup d’avantages par rapport à ces dernières : possibilité de les conserver au congélateur, peu immunogènes, ne provoquant pas d’embolies, pas de risque de différentiation anarchique, etc. Toutefois, l’utilisation en clinique de ces vésicules reste difficile pour des raisons pratiques : très faible production par les cellules, difficulté à les caractériser, méthodes de chargement avec des agents thérapeutique peu reproductible, méthodes d’imagerie ou de d’ingénierie peu efficientes, etc. Nous avons développé des méthodes pour répondre à ces défis, croisant la biologie, la pharmacie et la physique, et avons pu découvrir que certaines de ces techniques pouvaient être utilisées dans d’autres domaines et pour d’autres indications. En pratique, pour répondre au problème de la caractérisation des vésicules, nous avons proposé une nouvelle méthode d’imagerie utilisant le microscope électronique en cellule liquide « in situ » pour observer des vésicules dans leur milieu liquide en temps réel, et peut être utilisé pour observer d’autres matériaux et phénomènes comme les liposomes ou des processus biologiques. Nous avons proposé une nouvelle méthode de chargement des vésicules avec des molécules thérapeutiques en les fusionnant avec des liposomes, permettant la délivrance d’agents de chimiothérapie plus efficacement que des liposomes. La méthode de production des vésicules à grand rendement a nécessité 3 d’itérations successives, toutes basées sur le même concept de vésiculation induite par une contrainte mécanique, et a abouti à une méthode efficace, scalable, et conformes aux standards de production pharmaceutique. La protéomique de ces vésicules montre des expressions de protéines plus proche d’un sous type de vésicule issues de la membrane plasmique appelées microvésicules. Les vésicules issues de cette méthode ont été testées in vitro avec succès, induisent un phénotype régénératif dans des modèles cicatrisation de fistule cutanéo-digestives et des modèles murins d’insuffisance cardiaque chronique. D’autres études sur les vésicules produites par cette méthode sont en cours sur la régénération osseuse, articulaire et cérébrale, ou la délivrance de médicaments et sur l’inhibition du phénomène métastatique en cancérologie. Nous commençons aujourd’hui à défricher le transfert de ces vésicules en clinique par le biais de productions en conditions pharmaceutiques dites et de la mise en place d’une start-up.
- Open Access
- 19 July 2025
- Published by Springer Nature in PharmacoEconomics
- Vol. 43 (10) , 1205-1222
Integrating Environmental Impact in Health Technology Assessment: An Exploratory Study
To what extent a care pathway, due to its associated pollution, may be more detrimental to future health than beneficial to contemporary patients is still an open question. We present a methodological framework to integrate pollutant-induced future health damages in health technology assessment (HTA) metrics like quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) for a better evaluation of the cost effectiveness of care pathways. We used the ReCiPe model to estimate the future detrimental health impact (in disability-adjusted life years [DALY]) of pollutants from the US healthcare system, showing the major impact of GHG emissions compared with other pollutants. An adapted version of the ReCiPe model was used to convert GHG emissions from care pathways into future DALYGHG, QALYGHG, and life years (LYGHG), as well as the associated confidence intervals. For a given care pathway, future health damages were compared with patient benefits (e.g., QALYGHG/QALYpatient). Damages may also be integrated in the ICERGHG by subtracting future health losses from patient health benefits. Case applications are provided. Future damages to health emerging from pollutants emitted by the US healthcare system were estimated at 7,363,000 DALYs per year. Focusing on GHG emissions to estimate pollutant impact is reasonable, as they represent >90% of future damages. We provide estimates to convert GHG emissions into future health damages in DALY, QALY, or LY (and associated uncertainty), taking into account future impacts over different time horizons (20, 100, or 500-1000 years) and using different discount rates for future health impact (0 or 3%). We recommend estimating future damages using an egalitarian perspective (with a 0% discount rate) to maintain intergenerational equity. The QALYGHG/QALYpatient ratio allows weighting future detrimental effects of care pathways against their benefits. For health economic evaluations, we recommend integrating GHG emissions into the ICER, preferably in its denominator (QALY, DALY, LY). When focusing on specific care pathways, health gains may be substantially limited by future GHG-related detrimental impacts, especially for chronic treatments in low-risk populations. Some care pathways, like influenza vaccination, improve patient health while mitigating GHG. Accounting for GHG emissions may substantially favor or penalize one strategy over another in terms of ICER. Confidence intervals of the results were wide due to large uncertainties regarding long-term predictions. HTA should consider care pathways' impact on future health to better assess the impact and cost effectiveness of health technologies. Under the hypothesis of intergenerational equity, GHG accounting has a substantial impact, and may presumably impact the decisions of HTA bodies. It may also be seen as an ecological bonus/malus for care pathway developers and pharmaceutical companies, incentivizing the development of greener care pathways. None.
- 19 July 2025
- Published by Springer Nature in PharmacoEconomics
- Vol. 43 (10) , 1205-1222
Open AccessIntegrating Environmental Impact in Health Technology Assessment: An Exploratory Study
To what extent a care pathway, due to its associated pollution, may be more detrimental to future health than beneficial to contemporary patients is still an open question. We present a methodological framework to integrate pollutant-induced future health damages in health technology assessment (HTA) metrics like quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) for a better evaluation of the cost effectiveness of care pathways. We used the ReCiPe model to estimate the future detrimental health impact (in disability-adjusted life years [DALY]) of pollutants from the US healthcare system, showing the major impact of GHG emissions compared with other pollutants. An adapted version of the ReCiPe model was used to convert GHG emissions from care pathways into future DALYGHG, QALYGHG, and life years (LYGHG), as well as the associated confidence intervals. For a given care pathway, future health damages were compared with patient benefits (e.g., QALYGHG/QALYpatient). Damages may also be integrated in the ICERGHG by subtracting future health losses from patient health benefits. Case applications are provided. Future damages to health emerging from pollutants emitted by the US healthcare system were estimated at 7,363,000 DALYs per year. Focusing on GHG emissions to estimate pollutant impact is reasonable, as they represent >90% of future damages. We provide estimates to convert GHG emissions into future health damages in DALY, QALY, or LY (and associated uncertainty), taking into account future impacts over different time horizons (20, 100, or 500-1000 years) and using different discount rates for future health impact (0 or 3%). We recommend estimating future damages using an egalitarian perspective (with a 0% discount rate) to maintain intergenerational equity. The QALYGHG/QALYpatient ratio allows weighting future detrimental effects of care pathways against their benefits. For health economic evaluations, we recommend integrating GHG emissions into the ICER, preferably in its denominator (QALY, DALY, LY). When focusing on specific care pathways, health gains may be substantially limited by future GHG-related detrimental impacts, especially for chronic treatments in low-risk populations. Some care pathways, like influenza vaccination, improve patient health while mitigating GHG. Accounting for GHG emissions may substantially favor or penalize one strategy over another in terms of ICER. Confidence intervals of the results were wide due to large uncertainties regarding long-term predictions. HTA should consider care pathways' impact on future health to better assess the impact and cost effectiveness of health technologies. Under the hypothesis of intergenerational equity, GHG accounting has a substantial impact, and may presumably impact the decisions of HTA bodies. It may also be seen as an ecological bonus/malus for care pathway developers and pharmaceutical companies, incentivizing the development of greener care pathways. None.
- Top Cited PapersOpen Access
- 20 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-9
Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial
Endometrial cancers are characterized by frequent alterations in the PI3K-AKT-mTor, IGF1 and DNA repair signaling pathways. Concomitant inhibition of these pathways was warranted. ENDOLA phase I/II trial (NCT02755844) was designed to assess the safety/efficacy of the triplet combination of the PARP inhibitor olaparib, metronomic cyclophosphamide (50 mg daily), and PI3K-AKT-mTor inhibitor metformin (1500 mg daily) in women with recurrent endometrial carcinomas. Olaparib dose-escalation (100-300 mg twice-a-day (bid)) was used to determine the recommended-phase II-trial-dose (RP2D, primary endpoint), followed by an expansion cohort to determine the non-progression rate at 10 weeks (NPR-10w, secondary endpoint). 31 patients were treated. Olaparib RP2D was defined as 300 mg bid. The tolerability was acceptable, and grade 3-4 adverse events (51% patients) were mainly hematological. The NPR-10w was 61.5%, and the median progression-free survival (mPFS) was 5.2 months. In a post-hoc analysis, when explored by molecular subtypes/alterations, longer PFS were observed in patients with tumors characterized by a non-specific-molecular-profile (NSMP, n = 4; mPFS, 9.1 months), and by both TP53 altered & high number of large genomic alterations (LGA ≥ 8)(n = 10, mPFS, 8.6 months)). The analyses about kinetics of circulating biomarkers and pharmacodynamic effects are not reported here. In total, the benefit/toxicity ratio of the all-oral olaparib/cyclophosphamide/metformin regimen was favorable in heavily pretreated patients with recurrent endometrial cancer.
- 20 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-9
Top Cited PapersOpen AccessOlaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial
Endometrial cancers are characterized by frequent alterations in the PI3K-AKT-mTor, IGF1 and DNA repair signaling pathways. Concomitant inhibition of these pathways was warranted. ENDOLA phase I/II trial (NCT02755844) was designed to assess the safety/efficacy of the triplet combination of the PARP inhibitor olaparib, metronomic cyclophosphamide (50 mg daily), and PI3K-AKT-mTor inhibitor metformin (1500 mg daily) in women with recurrent endometrial carcinomas. Olaparib dose-escalation (100-300 mg twice-a-day (bid)) was used to determine the recommended-phase II-trial-dose (RP2D, primary endpoint), followed by an expansion cohort to determine the non-progression rate at 10 weeks (NPR-10w, secondary endpoint). 31 patients were treated. Olaparib RP2D was defined as 300 mg bid. The tolerability was acceptable, and grade 3-4 adverse events (51% patients) were mainly hematological. The NPR-10w was 61.5%, and the median progression-free survival (mPFS) was 5.2 months. In a post-hoc analysis, when explored by molecular subtypes/alterations, longer PFS were observed in patients with tumors characterized by a non-specific-molecular-profile (NSMP, n = 4; mPFS, 9.1 months), and by both TP53 altered & high number of large genomic alterations (LGA ≥ 8)(n = 10, mPFS, 8.6 months)). The analyses about kinetics of circulating biomarkers and pharmacodynamic effects are not reported here. In total, the benefit/toxicity ratio of the all-oral olaparib/cyclophosphamide/metformin regimen was favorable in heavily pretreated patients with recurrent endometrial cancer.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
Supplementary Data 1 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
Supplementary Data 1 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data and methods 4 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
Supplementary Data and methods
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data and methods 4 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
Supplementary Data and methods